Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06256588 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Study acronym: JADE
StatusRecruiting
PhasePhase 3
Started2024-03-21
View on ClinicalTrials.gov ↗
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)

Amendment record

Amended 5 times since 2024-02-05; most recent filed 2026-05-21. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-31.

2026-05-21
Amendment Study Status, Contacts/Locations v5
2025-09-22
Amendment Study Status, Study Description, Outcome Measures, Eligibility, Contacts/Locations v4
2025-05-28
Amendment Study Identification, Study Status, Contacts/Locations v3
2024-07-26
Amendment Study Identification, Study Status, Eligibility, Contacts/Locations v2
2024-05-27
Amendment Not Yet Recruiting→Recruiting Study Status, Eligibility, Contacts/Locations v1
2024-02-05
Original filing
Trial Details
NCT Number NCT06256588
Lead Sponsor GlaxoSmithKline
Conditions Neoplasms, Head and Neck
Enrollment 864 participants
Start Date 2024-03-21
Primary Completion 2028-06-30 (estimated)
Study Completion 2029-10-26 (estimated)
Updated on ClinicalTrials.gov 2026-05-26